It has been pointed out that the United States, which is trying to somehow increase the number of vaccinations, should not only look too much at its own situation, but also turn its attention to the international community. There is. However, there is another negative voice coming out here in Europe. “Quality could be another problem if patents were released,” he said. “It’s a better way for the United States to lift restrictions on vaccine exports.
This is Yeo Do-hyun.
In the United States, drug manufacturing patents are protected for 20 years.
During this period, the patented company can earn exclusively sales revenue.
It’s a kind of reward for innovation.
However, the United States recently said it would waive IPR protection for vaccines.
This is because of public opinion that more vaccines should be supplied to the world as the corona situation worsens, such as India.
The EU rebelled.
Vaccine production requires a lot of raw materials and technologies, but if the patent right is released, the quality is not controlled and it is more dangerous.
Instead, he stressed that the priority is to export more vaccines that the United States has accumulated in the country.
[우르줄라 폰데어라이엔/EU 집행위원회 위원장 : 지식재산권 보호 면제는 문제를 해결하지 못할 것이고…(필요한 것은) 우선, 백신 공유입니다. 둘째로 생산되고 있는 백신의 수출입니다.]